← The Wire·Breaking·Earnings·

Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance

Medtronic reported first-quarter fiscal 2027 results with broad-based growth across its largest franchises and new growth platforms, and raised its fiscal 2027 guidance. The company points to recent portfolio investments as supporting a longer-term growth trajectory, setting a higher bar for the rest of the fiscal year.

PR NEWSWIRE / FILE

The story

Medtronic's fiscal first-quarter 2027 report, released Tuesday from its Galway, Ireland base, showed the company's full-year revenue run rate at $36.4 billion, up 8.4% year over year, alongside diluted earnings per share of $3.73. The company characterized the quarter as one of broad-based portfolio performance, meaning growth was not concentrated in a single device category but spread across its largest franchises as well as newer growth platforms that management has been building out through recent acquisitions and internal investment. On the back of this performance, Medtronic raised its guidance for the full fiscal 2027 year, signaling management's confidence that the current growth rate is durable rather than a one-quarter anomaly.

The update comes against a backdrop in which Medtronic has spent several years working to diversify beyond its legacy cardiac and spine businesses, investing in areas such as diabetes technology, robotic-assisted surgery, and renal denervation. Prior quarters have shown the company narrating a story of gradual margin and growth improvement as newer platforms scale, and today's report appears to extend that narrative with an actual guidance raise rather than just a reaffirmation. That distinction matters: reaffirming guidance signals stability, while raising it signals that management sees more evidence than the market had already priced in.

The mechanism connecting the headline to Medtronic's shareholders is straightforward: an 8.4% year-over-year revenue growth rate, if sustained, flows through a large, relatively fixed-cost medtech manufacturing and R&D base, which can produce operating leverage and support the higher guidance. The

Our read · Tue, Sep 1

MDT's guidance raise on 8.4% revenue growth and $3.73 diluted EPS shifts the near-term evidence toward the bull case for the stock.

Why. A guidance raise off broad-based growth (8.4% YoY revenue, $3.73 diluted EPS) is a rare positive datapoint for a large-cap medtech name that has spent years defending a slow-growth narrative, and it tends to reset sell-side numbers higher into the next print. The read is grounded in the filed figures rather than sentiment, which supports a modest long bias without demanding an aggressive target.

Both cases

The case it holdsAn 8.4% YoY revenue growth rate paired with a full-year guidance raise suggests newer platforms (diabetes, surgical robotics, renal denervation) are scaling faster than the market had modeled, which could justify further estimate revisions.
The case it breaksMedtronic has repeatedly guided cautiously in the past only to see margin execution lag revenue growth, so a single strong quarter and raise does not guarantee the higher bar holds through the full fiscal year.

What could change this view: Medtech names carry tariff, FX, and device-recall tail risk that can quickly offset topline momentum; a strong quarter does not immunize against a subsequent product-specific setback.

Medtronic stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Keep reading

More on MDT

Medtronic sets 4.5939 final exchange ratio for MiniMed split-off

Latest on the Wire

BlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultAnthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by PR Newswire, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →